Novartis India Limited has filed a disclosure pursuant to Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended. The disclosure pertains to the sale of equity shares by Novartis AG, the promoter of the company.
Nature of the Event
Novartis AG sold 1,74,50,680 equity shares of Novartis India Limited, representing 70.68% of the total share capital and total diluted share/voting capital. The transaction was completed on Wednesday, July 29, 2026.
Transaction Details
The sale was executed as an off-market sale pursuant to the Agreement for the sale and purchase of the Sale Shares in Novartis India Limited dated February 19, 2026.
Ownership Change and Reclassification
Prior to this sale, Novartis AG held 1,74,50,680 equity shares (70.68% of voting rights) and was classified as the promoter. Following the complete divestment of its entire holding, Novartis AG has ceased to hold any equity shares in Novartis India Limited. Consequently, it stands reclassified from the 'promoter' category to a 'public' category shareholder in accordance with Regulation 31A(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Its post-transaction holding is nil (0 shares).
Capital Structure Impact
The total paid-up equity share capital of Novartis India Limited both before and after the transaction remains unchanged at ₹12,34,53,985, comprising 2,46,90,797 fully paid-up equity shares of face value ₹5 each. The total diluted share/voting capital also remains the same at ₹12,34,53,985.
Filing and Acknowledgement
The disclosure was submitted to BSE Limited and the Board of Directors of Novartis India Limited for their records and acknowledgement of receipt. It was also made available on the company's website at www.nilpharma.co.in.